低リスク肺塞栓症患者における癌患者に対する抗凝固療法の最適期間

基本情報

NCT ID: NCT04724460
ステータス: 完了
試験のフェーズ: 第4相
試験タイプ: 介入
目標被験者数: 179
治験依頼者名: Kyoto University, Graduate School of Medicine

概要

The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmonary embolism patients. The major secondary purpose of this study is to investigate whether home treatment of cancer-associated low-risk pulmonary embolism patients with rivaroxaban is feasible, effective, and safe through an observational management study.

対象疾患

Venous ThrombosisNeoplasmsAnticoagulants

介入

Long DOAC(DRUG)

Short DOAC(DRUG)

依頼者（Sponsor）

バイエル薬品株式会社(INDUSTRY)

Takeshi Morimoto(OTHER)

実施施設 (1)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Kyoto, Kyoto, Japan